MedTrace Logo

Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis

NCT02966522 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-10-26

No results posted yet for this study

Summary

To prove the organ-reversing potential of thalidomide for amyloidosis with cardiac involvement

Conditions

  • Cardiac Amyloidosis

Interventions

DRUG

Thalidomide

DRUG

Dexamethasone

Sponsors & Collaborators

  • CW pharmaceutical company

    collaborator UNKNOWN

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Youngil Koh, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02966522 on ClinicalTrials.gov